Financings Of The Fortnight Sees New Biotech Funding All Over The Globe, And Without Much VC Participation
This article was originally published in The Pink Sheet Daily
Executive Summary
Plus news on recent financial activity by Merrimack, Promethera, ADC Therapeutics and Enterome Bioscience.
You may also be interested in...
Financings Of The Fortnight: In The Aftermath Of Facebook IPO, Kythera Steps Up, TVAX And Cancer Genetics Back Off
Plus news on recent financing activity by TVM Capital, Royalty Pharma, Prosonix and Sangart.
Lilly And Canadian VCs To Fund TVM Life Sciences VII To Develop Single-Asset Companies
Lilly and Canadian VCs back a new TVM Life Sciences fund that will invest in a network of single-asset companies in Quebec.
New $80 Million U.K. Asset-Centric Cancer Research Fund Set Up With EU, Charity Funding
The U.K.'s Cancer Research Technology and the European Investment Fund join forces to launch an asset-centric investment fund to bridge the development gap, the third new U.K. fund in two weeks.